Department of Infectious Diseases, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands.
Department of Internal Medicine, Haga Hospital, PO Box 40551, 2504 LN, The Hague, the Netherlands.
J Infect. 2018 Jul;77(1):18-24. doi: 10.1016/j.jinf.2018.05.007. Epub 2018 May 26.
Febrile urinary tract infections (fUTI) can often be treated safely with oral antimicrobials in an outpatient setting. However, a minority of patients develop complications that may progress into septic shock. An accurate assessment of disease severity upon emergency department (ED) presentation is therefore crucial in order to guide the most appropriate triage and treatment decisions.
Consecutive patients were enrolled with presumptive fUTI across 7 EDs in the Netherlands. The biomarkers mid-regional proadrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), and a clinical score (PRACTICE), were compared in their ability to predict a clinically severe course of fUTI, initial hospital admission and subsequent readmission using area under the receiver operating characteristic (AUROC) curves.
Biomarker concentrations were measured in 313 patients, with 259 (83%) hospitalized upon ED presentation, and 54 (17%) treated as outpatients. Of these outpatients, 12 (22%) were later hospitalized. MR-proADM had the highest diagnostic accuracy for predicting a complicated fUTI (AUROC [95% CI]: 0.86 [0.79-0.92]), followed by PCT (AUROC [95% CI]: 0.69 [0.58-0.80]). MR-proADM concentrations were unique in being significantly elevated in patients directly admitted and in outpatients requiring subsequent hospitalization, compared to those completing treatment at home. A virtual triage algorithm with an MR-proADM cut-off of 0.80 nmol/L resulted in a hospitalization rate of 66%, with only 2% secondary admissions.
MR-proADM could accurately predict a severe course in patients with fUTI, and identify greater patient numbers who could be safely managed as outpatients. An initial assessment on ED presentation may focus resources to patients with highest disease severities.
发热性尿路感染(fUTI)通常可以在门诊环境下安全地使用口服抗生素治疗。然而,少数患者会出现并发症,这些并发症可能发展为感染性休克。因此,在急诊科(ED)就诊时准确评估疾病严重程度对于指导最合适的分诊和治疗决策至关重要。
连续纳入了荷兰 7 家 ED 中疑似 fUTI 的患者。比较了中区域前肾上腺髓质素(MR-proADM)、降钙素原(PCT)、C 反应蛋白(CRP)和临床评分(PRACTICE)这 4 种生物标志物预测 fUTI 严重临床病程、初始住院和随后再入院的能力,使用接受者操作特征曲线(AUROC)下面积。
共测量了 313 名患者的生物标志物浓度,其中 259 名(83%)在 ED 就诊时住院,54 名(17%)作为门诊患者接受治疗。其中,12 名(22%)门诊患者后来住院。MR-proADM 预测复杂 fUTI 的诊断准确性最高(AUROC [95%CI]:0.86 [0.79-0.92]),其次是 PCT(AUROC [95%CI]:0.69 [0.58-0.80])。与在家中完成治疗的患者相比,直接住院和需要后续住院的门诊患者的 MR-proADM 浓度显著升高。MR-proADM 截断值为 0.80 nmol/L 的虚拟分诊算法导致住院率为 66%,仅有 2%的患者需要再次入院。
MR-proADM 可准确预测 fUTI 患者的严重病程,并识别出更多可安全作为门诊患者管理的患者。ED 就诊时的初步评估可以将资源集中在疾病严重程度最高的患者身上。